Protein C Level in Type 2 Diabetic Patients with Ischemic Heart Disease
Keywords:
Protein C Level, Type 2 Diabetic, Ischemic Heart Disease, Coronary AngiographyAbstract
Background: Diabetes Mellitus is among the most important risk factors for the development of cardiovascular diseases. Macro vascular complications associated with diabetes, namely, coronary artery disease, cerebro vascular disease and peripheral vascular disease are mainly due to accelerated atherosclerosis. The aim of this work was to assess the relationship of the level of protein C in diabetic patients with ischemic heart disease versus normal individuals.
Methods: case control study conducted on 90 with subjects who were classified into three equal groups: Group 1: diabetic patients without ischemic heart disease (normal coronary angiography). Group 2: diabetic patients with ischemic heart disease (with cardiac ischemia on coronary angiography). Group 3: Normal individuals as control.
Results: The mean Protein C level was highest in the Control group followed by DM without IHD group and lowest in DM with IHD group. Protein C demonstrated good diagnostic performance in discriminating between diabetes groups. Protein C achieved an AUC of 0.731 and an accuracy of 78.3%. The optimal cut-off value of 64 provided a sensitivity of 93.33% and a specificity of 63.33%.
Conclusions: Protein C levels were significantly lower in diabetic patients, especially those with ischemic heart disease (IHD), compared to healthy controls, linking Protein C deficiency to thrombotic complications. Multivariate analysis identified low Protein C levels and smoking as independent predictors of IHD severity. Protein C demonstrated strong diagnostic capability, indicating its potential as a useful biomarker for identifying vascular risk in diabetes..
Downloads
References
Dokken BB. The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids. Diabetes Spectrum.21(3):160-5. 2008. Doi:10.2337/diaspect.21.3.160.
Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab.20(4):546-51. 2016. Doi:10.4103/2230-8210.183480.
Chandy A, Pawar B, John M, Isaac R. Association between diabetic nephropathy and other diabetic microvascular and macrovascular complications. Saudi J Kidney Dis Transpl.19(6):924-8. 2008.
Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes.5(4):444-70. 2014. Doi:10.4239/wjd. v5.i4.444.
Bloomgarden ZT. Cardiovascular disease in diabetes. American Diabetes Association; 2010.
Kim HK, Kim JE, Park SH, Kim YI, Nam-Goong IS, Kim ES. High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications. J Diabetes Complications.28(3):365-9. 2014. Doi: 10.1016/j.jdiacomp.2014.01.006.
Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications.15(1):44-54. 2001. Doi:10.1016/s1056-8727(00)00132-x.
Taggart C, Wereski R, Mills NL, Chapman AR. Diagnosis, Investigation and Management of Patients with Acute and Chronic Myocardial Injury. J Clin Med.10(11). 2021. Doi:10.3390/jcm10112331.
Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. JACC.58(24): e44-e122. 2011. Doi: doi: 10.1016/j.jacc.2011.08.007.
Neeland IJ, Patel RS, Eshtehardi P, Dhawan S, McDaniel MC, Rab ST, et al. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. Am Heart J.164(4):547-52. e1. 2012. Doi: 10.1016/j.ahj.2012.07.007.
Aktaş HŞ, Ucak S, Demirbaş MB, Sarikaya Z, Olçum GG, Pınar E. The relation of protein C and protein S levels with cardiovascular risk in patients with diabetic neuropathy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews.10(4):234-7. 2016. Doi: https://doi.org/10.1016/j.dsx.2016.06.015.
Katerina Thisiadou IK, Stella Arampatzi & Despoina Lazaridou. Coagulation inhibitors in type 2 diabetes mellitus. 12th European Congress of Endocrinology 2010. p. P291.
Aktas HS, Ucak S, Demirbas MB, Sarikaya Z, Olcum GG, Pinar E. The relation of protein C and protein S levels with cardiovascular risk in patients with diabetic neuropathy. Diabetes Metab Syndr.10(4):234-7. 2016. Doi: 10.1016/j.dsx.2016.06.015.
Mahmoodi BK, Brouwer J-LP, Veeger NJGM, van der Meer J. Hereditary Deficiency of Protein C or Protein S Confers Increased Risk of Arterial Thromboembolic Events at a Young Age. Circulation.118(16):1659-67. 2008. Doi:10.1161/CIRCULATIONAHA.108.780759.
Salehi N, Janjani P, Tadbiri H, Rozbahani M, Jalilian M. Effect of cigarette smoking on coronary arteries and pattern and severity of coronary artery disease: a review. Journal of International Medical Research.49(12):03000605211059893. 2021. Doi:10.1177/03000605211059893.
Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, et al. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes care.25(8):1439-43. 2002.
Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. Jama.286(4):421-6. 2001.
Addai-Mensah O, Annani-Akollor ME, Nsafoah FO, Fondjo LA, Owiredu EW, Danquah KO, et al. Effect of poor glycaemic control on plasma levels and activity of protein C, protein S, and antithrombin III in type 2 diabetes mellitus. PLoS One.14(9): e0223171. 2019. Doi: 10.1371/journal.pone.0223171.
Shrivastav D, Dabla PK, Singh DD, Mehta V. Type 2 diabetes mellitus and coronary artery stenosis: a risk pattern association study. Exploration of Medicine.4(3):336-42. 2023.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
